These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23420374)
1. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374 [TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429 [TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450 [TBL] [Abstract][Full Text] [Related]
6. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis. Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Misawa K; Ueda Y; Kanazawa T; Misawa Y; Jang I; Brenner JC; Ogawa T; Takebayashi S; Grenman RA; Herman JG; Mineta H; Carey TE Clin Cancer Res; 2008 Dec; 14(23):7604-13. PubMed ID: 19047085 [TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140 [TBL] [Abstract][Full Text] [Related]
11. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494 [TBL] [Abstract][Full Text] [Related]
12. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635 [TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299 [TBL] [Abstract][Full Text] [Related]
14. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Misawa K; Kanazawa T; Misawa Y; Uehara T; Imai A; Takahashi G; Takebayashi S; Cole A; Carey TE; Mineta H Transl Oncol; 2013 Jun; 6(3):338-46. PubMed ID: 23730414 [TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327 [TBL] [Abstract][Full Text] [Related]
17. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. Weiss D; Stockmann C; Schrödter K; Rudack C Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585 [TBL] [Abstract][Full Text] [Related]
18. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma. Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364 [TBL] [Abstract][Full Text] [Related]
20. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene. Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]